(VEGFR2+) CECs, (CD133+) HPCs, plasma vascular endothelial growth factor (VEGF) and erythropoietin were measured in blood from 25 non-small cell lung cancer (NSCLC) patients before and during treatment with sorafenib plus erlotinib (SO/ER). The gene discussed is PROM1; the disease is non-small cell lung carcinoma.